• Explore /
  • Poster
  • / Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.

Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.

Abstract Poster

Authors

Gail Roboz

Gail J. Roboz

Weill Cornell Medical College, New York, NY

Gail J. Roboz , Courtney Denton Dinardo , Eytan M. Stein , Stéphane de Botton , Alice S. Mims , Gabrielle T. Prince , Jessica K. Altman , Martha Lucia Arellano , Harry Paul Erba , Daniel Aaron Pollyea , Anthony Selwyn Stein , Justin M. Watts , Amir Tahmasb Fathi , Hagop M. Kantarjian , Martin S. Tallman , Bin Fan , Hua Liu , Bin Wu , Eyal C. Attar , Richard M. Stone

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT02074839

Citation

J Clin Oncol 37, 2019 (suppl; abstr 7028)

DOI

10.1200/JCO.2019.37.15_suppl.7028

Abstract #

7028

Poster Bd #

403

Abstract Disclosures

Similar Posters

First Author: Hartmut Dohner

First Author: David Dai

First Author: Chengyuan Gu

First Author: Shen Zhao